Expression and prognostic value of MCM2 in type B thymomas.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-10-03 DOI:10.1186/s12885-025-14807-4

Xin Du, Jian Cui, Xintao Yu, Dingfang Cao, Ying Zhang, Lei Yu, Shanqing Li

{"title":"Expression and prognostic value of MCM2 in type B thymomas.","authors":"Xin Du, Jian Cui, Xintao Yu, Dingfang Cao, Ying Zhang, Lei Yu, Shanqing Li","doi":"10.1186/s12885-025-14807-4","DOIUrl":null,"url":null,"abstract":"Background: Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.Methods: mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2's association with prognosis and clinicopathological features.Results: Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05-0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08-0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.Conclusions: MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1506"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495699/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14807-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Thymic epithelial tumors (TETs) are the most common mediastinal malignancies, lacking reliable prognostic biomarkers. This study aimed to identify a potential prognostic marker for TETs.

Methods: mRNA microarray analysis of 30 tumor and peritumoral tissues identified differentially expressed genes (DEGs). Hub genes were selected via protein-protein interaction (PPI) analysis, with MCM2 chosen as the target gene. Survival and enrichment analyses were performed, and a validation cohort assessed MCM2's association with prognosis and clinicopathological features.

Results: Seven hundred thirty-four DEGs were identified, with MCM2 significantly associated with prolonged progression-free survival (PFS) (HR = 0.17; 95% CI: 0.05-0.54; p = 0.003) and identified as an independent risk factor for PFS (HR = 0.26; 95% CI: 0.08-0.91; p = 0.035). MCM2 expression decreased from type B1 to B3 thymomas.

Conclusions: MCM2 is an independent prognostic factor for TETs, with higher expression linked to better PFS and decreasing expression across B-type thymomas, suggesting its role as a favorable prognostic marker.

查看原文本刊更多论文

MCM2在B型胸腺瘤中的表达及预后价值。

背景：胸腺上皮肿瘤（TETs）是最常见的纵隔恶性肿瘤，缺乏可靠的预后生物标志物。本研究旨在确定tet的潜在预后标志物。方法：对30例肿瘤及瘤周组织进行mRNA微阵列分析，鉴定差异表达基因（DEGs）。通过蛋白-蛋白相互作用（PPI）分析筛选枢纽基因，选择MCM2作为靶基因。进行生存和富集分析，验证队列评估MCM2与预后和临床病理特征的关系。结果：共鉴定出734例deg， MCM2与延长无进展生存期（PFS）显著相关（HR = 0.17; 95% CI: 0.05-0.54; p = 0.003），并被鉴定为PFS的独立危险因素（HR = 0.26; 95% CI: 0.08-0.91; p = 0.035）。从B1型胸腺瘤到B3型胸腺瘤MCM2表达降低。结论：MCM2是一个独立的TETs预后因子，其高表达与较好的PFS相关，而在b型胸腺瘤中表达降低，提示其作为一个有利的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.